
# DRUG-ELUTING PTCA BALLOON DILATATION CATHETER

#### PTX MICROPARTICLES WITH 99.9% PURE DRUG

Novel needle-shaped PTX microparticles


### Pure matrix, crystal delivery






211 patients with coronary stent restenosis, coronary angiography and clinical follow-up observations were performed at ninth month after the operation:

#### Outer diameter lower than the competition



balloon size: 3.5\*20mm


#### Pharmacokinetic data shows high Concentration of paclitaxel in tissue and sustained therapeutic effect



	ZMD	SeQuent <sup>®</sup> Please	P value
Preoperative target lesion stenosis degree (%)	67.65±16.56	66.76±13.78	0.657
Restenosis within the target lesion segment after 9 months (%)	10.34	10.58	0.858
Target lesion failure rate in 9 months after operation (%)	4.76	4.72	0.953
Incidence of thrombotic events (%)	0.95	0.94	0.945

#### **ORDERING INFORMATION**

Diameter of balloon (mm)	Effective length of balloon (mm)						
	10	15	17	20	26	30	
2.00	G2.00-10	G2.00-15	G2.00-17	G2.00-20	G2.00-26	G2.00-30	
2.50	G2.50-10	G2.50-15	G2.50-17	G2.50-20	G2.50-26	G2.50-30	
2.75	G2.75-10	G2.75-15	G2.75-17	G2.75-20	G2.75-26	G2.75-30	
3.00	G3.00-10	G3.00-15	G3.00-17	G3.00-20	G3.00-26	G3.00-30	
3.50	G3.50-10	G3.50-15	G3.50-17	G3.50-20	G3.50-26	G3.50-30	
4.00	G4.00-10	G4.00-15	G4.00-17	G4.00-20	G4.00-26	G4.00-30	



## **COMPLIANCE CHART**

Pressure (atm)	Balloon length (mm)					
Pressure (atili)	2.00	2.50	2.75	3.00	3.50	4.00
2	1.87	2.36	2.59	2.82	3.29	3.77
4	1.94	2.43	2.67	2.91	3.39	3.89
6	2.00	2.50	2.75	3.00	3.50	4.00
	2.06		2.83	3.09	3.61	4.11
10	2.13	2.64	2.91	3.18	3.71	4.23
12	2.19		2.98	3.27	3.82	4.34
14Rated bursting pressure	2.25	2.78	3.06	3.36	3.92	4.45
16	2.32	2.85	3.14	3.45	4.03	4.57
18	2.38	2.92	3.22	3.54	4.14	A

<sup>\*</sup> Nominal Pressure. The nominal in vitro device specifications do not take into account any lesion resistance.\* \*Rated Burst Pressure. Do not exceed RBP.